Publicacións en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (31)

2024

  1. Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study

    Journal of Nutrition, Health and Aging, Vol. 28, Núm. 8

  2. Genome-wide DNA methylation profiling in tongue squamous cell carcinoma

    Oral Diseases, Vol. 30, Núm. 2, pp. 259-271

  3. Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

    Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 1896-1907

  4. Inhibition of acyl-CoA binding protein (ACBP) by means of a GABAARγ2-derived peptide

    Cell Death and Disease, Vol. 15, Núm. 4

  5. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

  6. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

    Frontiers in Oncology, Vol. 14

  7. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

  8. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

2023

  1. A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

    Biomedicine and Pharmacotherapy, Vol. 159

  2. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

    ERJ Open Research, Vol. 9, Núm. 6

  3. An engineered periosteum for efficient delivery of rhBMP-2 and mesenchymal progenitor cells during bone regeneration

    npj Regenerative Medicine, Vol. 8, Núm. 1

  4. Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer

    Cancers, Vol. 15, Núm. 14

  5. Quantitative PET tracking of intra-articularly administered 89Zr-peptide-decorated nanoemulsions

    Journal of Controlled Release, Vol. 356, pp. 702-713

  6. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

    Cancer Treatment and Research Communications, Vol. 37

  7. SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2627-2633

  8. Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatic head and neck cancer using a next-generation sequencing panel: A preliminary study

    Cancer Medicine, Vol. 12, Núm. 6, pp. 6615-6622

2022

  1. Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study

    Cancers, Vol. 14, Núm. 19

  2. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

  3. Integrity and quantity of salivary cell-free DNA as a potential molecular biomarker in oral cancer: A preliminary study

    Journal of Oral Pathology and Medicine, Vol. 51, Núm. 5, pp. 429-435

  4. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

    Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800